NCT05795244
Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 3 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 167 words Show 6 more changesShow less
- Enrollment closed, study ongoing
- Trial sites expanded: 1 → 6 locations
- Primary completion date changed from estimate of Dec 2029 to Feb 24, 2026
- Study completion date: Dec 2029 to Dec 31, 2029
- Secondary endpoints: 3 to 4
- Publications: details revised at 1 of 1 entry
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Apr 2023 to Oct 31, 2023
- Site details revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
pathologic complete response
Timeframe: At 6 months
Secondary (4)
Objective response rate (ORR)
Progression free survival (PFS)
Overall survival (OS)
Incidence of Treatment-Emergent Adverse Events (TEAEs)
Arms and interventions
ExperimentalExperimental
Drugs: Nivolumab
Sites
6 sites in 1 country